Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent WHO Grade III Glioma: early-phase trial registry
2 of 7 indexed Recurrent WHO Grade III Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent WHO Grade III Glioma: 7 US clinical trials tracked, 2 recruiting.
Recurrent WHO Grade III Glioma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 3 of these trials.
Enrollment posture brief
Registry condition recurrent-who-grade-iii-glioma
OPEN 2 | RECR 29% | LATE 0 | EARLY 7 | RANK #2497 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)
Recurrent WHO Grade III Glioma lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent WHO Grade III Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent WHO Grade III Glioma is recruiting below its size-band peers.
2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent WHO Grade III Glioma research.
City of Hope Medical Center accounts for 3 of 7 trials (42.9%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent WHO Grade III Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Recurrent WHO Grade III Glioma research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
NCT05009992
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Susan Chang
NCT04540107
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT03749187
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
City of Hope Medical Center
NCT02208362
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
City of Hope Medical Center
NCT04214392
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
NCT02192359
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03914742
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent WHO Grade III Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent WHO Grade III Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent WHO Grade III Glioma page
7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Recurrent WHO Grade III Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Recurrent WHO Grade III Glioma trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent WHO Grade III Glioma condition card totals 7 registered trials; most-linked intervention PARP Inhibitor BGB-290; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.